Skip to main content

ASH 2021 - AML

MRD status at the time of allogeneic stem-cell transplantation and the number of remissions prior to transplant were shown to be important independent prognostic factors in patients with AML. Read More ›

Addition of venetoclax to FLAG-IDA yielded high minimal residual disease–negative composite complete response rates in newly diagnosed patients with AML, accompanied by a favorable safety profile. Read More ›

The phase 3 AGILE study demonstrated that ivosidenib + azacitidine therapy provided significant survival benefit compared with placebo plus azacitidine in patients with newly diagnosed IDH1 mutation–positive AML who were ineligible for intensive chemotherapy. Read More ›

AML patients who underwent allogeneic stem-cell transplantation from unrelated donors while in their second complete remission with post-transplant cyclophosphamide had similar outcomes to those who underwent transplantation while in first complete remission. Read More ›

In the first-in-human phase 1/2 AUGMENT 101 study, SNDX-5613 demonstrated an acceptable safety profile and promising antileukemic activity in patients with heavily pretreated relapsed/refractory MLL-rearranged and NPM1-mutated acute leukemias. Read More ›

Gilteritinib plus azacitidine led to significantly higher composite complete remission rates but did not provide a survival advantage compared with azacitidine alone in patients with newly diagnosed FLT3mut+ AML ineligible for intensive induction chemotherapy. Read More ›

In a retrospective analysis, upfront liposomal daunorubicin/cytarabine treatment was shown to accord an overall survival advantage compared with HMA + venetoclax, which, however, did not extend to complete response rates and recurrence-free survival. Read More ›

Results from an ongoing first-in-human phase 1/2 study indicated that the FLT3/SYK inhibitor HM43239 yielded a favorable safety profile and encouraging antileukemic activity in patients with relapsed/refractory AML regardless of FLT3 mutation status. Read More ›

Findings from a retrospective analysis suggested that venetoclax plus hypomethylating agent plus an FLT3 inhibitor led to significant improvement in clinical outcomes, in older and unfit patients with FLT3-mutated AML. Read More ›

Patients with treated secondary AML and prior hypomethylating exposure derived significant clinical benefit from hypomethylating agents plus venetoclax therapy compared with chemotherapy-based approaches. Read More ›

Page 1 of 2